Madrigal Pharma was the first drugmaker to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, and has now signed a major alliance with China’s Ribo Life Science to keep its pipeline for the liver disorder topped up.The licensing deal, which spans six preclinical-stage MASH candidates, includes an upfront payment to Ribo of $60 […]
